Competition-based domain allocation

Mechanistic description

Tau and MAP6 compete for microtubule binding sites in a concentration-dependent manner, with relative local abundance determining domain stability

Prediction: Artificially equalizing tau:MAP6 ratio on individual microtubules will produce intermediate stability domains with mixed molecular signatures

Mechanism / pathway

MAPT
→
neurodegeneration

Evidence for (5)

Antagonistic roles of tau and MAP6 in regulating neuronal development.

PMID:39257379 2024 J Cell Sci
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.

PMID:40044789 2025 Nat Struct Mol Biol
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.

PMID:30742061 2019 Lab Invest
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease.

PMID:36843263 2023 Autophagy
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.

PMID:37095250 2023 Nat Med

Evidence against (2)

Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance drives adult neurodegeneration progression or treatment response.

PMID:39257379 2024 J Cell Sci
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, cautioning against simple cytoskeletal-stabilization translation in tauopathy.

PMID:24873720 2014 Lancet Neurol

Evidence matrix

6 supporting 2 contradicting

53% posterior support

Supporting

Tau and MAP6 compete for microtubule binding sites in a concentration-dependent manner, with relative local abundance determining domain stability
Antagonistic roles of tau and MAP6 in regulating neuronal development. PMID:39257379 · 2024 · J Cell Sci
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W. PMID:40044789 · 2025 · Nat Struct Mol Biol
MAPT mutations, tauopathy, and mechanisms of neurodegeneration. PMID:30742061 · 2019 · Lab Invest
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease. PMID:36843263 · 2023 · Autophagy
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. PMID:37095250 · 2023 · Nat Med

Contradicting

Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance drives adult neurodegeneration progression or treatment response. PMID:39257379 · 2024 · J Cell Sci
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, cautioning against simple cytoskeletal-stabilization translation in tauopathy. PMID:24873720 · 2014 · Lancet Neurol

Bayesian persona consensus

53% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). Competition-based domain allocation. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-5bdd4e163c5a

BibTeX

@misc{scidex_hypothesis_h5bdd4e1,
  title        = {Competition-based domain allocation},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-5bdd4e163c5a},
  note         = {SciDEX artifact hypothesis:h-5bdd4e163c5a}
}